Crossmark

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab

Crossref DOI link: https://doi.org/10.1136/bmjno-2025-001477

Published Online: 2026-03-18

Published Print: 2026-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Høgestøl, Einar August https://orcid.org/0000-0001-8446-2111
Brustad, Åge Winje https://orcid.org/0000-0002-6390-3173
Celius, Elisabeth Gulowsen

Meling, Martine

Berg-Hansen, Pål https://orcid.org/0000-0003-2992-7195
Kro, Grete Birkeland

König, Marton

Schanke, Ylva

Halvorsen, Bente

Warren, David J

Gehin, Johanna E https://orcid.org/0000-0001-6242-9804
Bolstad, Nils

Nygaard, Gro Owren
License Information

License valid from 2026-03-17